Differences Between RSV A and RSV B Subgroups and Implications for Pharmaceutical Preventive Measures.
Clinical severity
Epidemiology
Monoclonal antibodies
RSV subgroups
Respiratory syncytial virus
Vaccines
Journal
Infectious diseases and therapy
ISSN: 2193-8229
Titre abrégé: Infect Dis Ther
Pays: New Zealand
ID NLM: 101634499
Informations de publication
Date de publication:
06 Jul 2024
06 Jul 2024
Historique:
received:
20
10
2023
accepted:
21
06
2024
medline:
7
7
2024
pubmed:
7
7
2024
entrez:
6
7
2024
Statut:
aheadofprint
Résumé
Understanding the differences between respiratory syncytial virus (RSV) subgroups A and B provides insights for the development of prevention strategies and public health interventions. We aimed to describe the structural differences of RSV subgroups, their epidemiology, and genomic diversity. The associated immune response and differences in clinical severity were also investigated. A literature review from PubMed and Google Scholar (1985-2023) was performed and extended using snowballing from references in captured publications. RSV has two major antigenic subgroups, A and B, defined by the G glycoprotein. The RSV F fusion glycoprotein in the prefusion conformation is a major target of virus neutralizing antibodies and differs in surface exposed regions between RSV A and RSV B. The subgroups co-circulate annually, but there is considerable debate as to whether clinical severity is impacted by the subgroup of the infecting RSV strain. Large variations between the studies reporting RSV subgroup impact on clinical severity were observed. A tendency for higher disease severity may be attributed to RSV A but no consensus could be reached as to whether infection by one of the subgroup caused more severe outcomes. RSV genotype diversity decreased over the last two decades, and ON and BA have become the sole lineages detected for RSV A and RSV B, since 2014. No studies with data obtained after 2014 reported a difference in disease severity between the two subgroups. RSV F is relatively well conserved and highly similar between RSV A and B, but changes in the amino acid sequence have been observed. Some of these changes led to differences in F antigenic sites compared to reference F sequences (e.g., RSV/A Long strain), which are more pronounced in antigenic sites of the prefusion conformation of RSV B. Initial results from the second season after vaccination suggest specific RSV B efficacy wanes more rapidly than RSV A for RSV PreF-based monovalent vaccines. RSV A and RSV B both contribute substantially to the global RSV burden. Both RSV subgroups cause severe disease and none of the available evidence to date suggests any differences in clinical severity between the subgroups. Therefore, it is important to implement measures effective at preventing disease due to both RSV A and RSV B to ensure impactful public health interventions. Monitoring overtime will be needed to assess the impact of waning antibody levels on subgroup-specific efficacy.
Identifiants
pubmed: 38971918
doi: 10.1007/s40121-024-01012-2
pii: 10.1007/s40121-024-01012-2
doi:
Types de publication
Journal Article
Review
Langues
eng
Informations de copyright
© 2024. Pfizer.
Références
Public Health England. Respiratory syncytial virus. The Green Book; 2015.
GBD 2016 Lower Respiratory Infections Collaborators. Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Infect Dis. 2018;18(11):1191–210.
Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med. 2005;352(17):1749–59.
pubmed: 15858184
doi: 10.1056/NEJMoa043951
McLaughlin JM, Khan F, Begier E, Swerdlow DL, Jodar L, Falsey AR. Rates of medically attended RSV among US adults: a systematic review and meta-analysis. Open Forum Infect Dis. 2022;9(7):ofac300.
pubmed: 35873302
pmcid: 9301578
doi: 10.1093/ofid/ofac300
Li Y, Kulkarni D, Begier E, et al. Adjusting for case under-ascertainment in estimating RSV hospitalisation burden of older adults in high-income countries: a systematic review and modelling study. Infect Dis Ther. 2023;12(4):1137–49.
pubmed: 36941483
pmcid: 10027261
doi: 10.1007/s40121-023-00792-3
Janet S, Broad J, Snape MD. Respiratory syncytial virus seasonality and its implications on prevention strategies. Hum Vaccin Immunother. 2018;14(1):234–44.
pubmed: 29194014
doi: 10.1080/21645515.2017.1403707
Chadha M, Hirve S, Bancej C, et al. Human respiratory syncytial virus and influenza seasonality patterns—early findings from the WHO global respiratory syncytial virus surveillance. Influenza Other Respir Viruses. 2020;14(6):638–46.
pubmed: 32163226
pmcid: 7578323
doi: 10.1111/irv.12726
Staadegaard L, Caini S, Wangchuk S, et al. The global epidemiology of RSV in community and hospitalized care: findings from 15 countries. Open Forum Infect Dis. 2021;8(7):ofab159.
pubmed: 34337092
pmcid: 8320297
doi: 10.1093/ofid/ofab159
Saravanos GL, Ramos I, Britton PN, Wood NJ. Respiratory syncytial virus subtype circulation and associated disease severity at an Australian paediatric referral hospital, 2014–2018. J Paediatr Child Health. 2021;57(8):1190–5.
pubmed: 33638925
doi: 10.1111/jpc.15419
Vandini S, Biagi C, Lanari M. Respiratory syncytial virus: the influence of serotype and genotype variability on clinical course of infection. Int J Mol Sci. 2017;18(8):1717.
pubmed: 28783078
pmcid: 5578107
doi: 10.3390/ijms18081717
Hause AM, Henke DM, Avadhanula V, Shaw CA, Tapia LI, Piedra PA. Sequence variability of the respiratory syncytial virus (RSV) fusion gene among contemporary and historical genotypes of RSV/A and RSV/B. PLoS ONE. 2017;12(4):e0175792.
pubmed: 28414749
pmcid: 5393888
doi: 10.1371/journal.pone.0175792
Tian D, Battles MB, Moin SM, et al. Structural basis of respiratory syncytial virus subtype-dependent neutralization by an antibody targeting the fusion glycoprotein. Nat Commun. 2017;8(1):1877.
pubmed: 29187732
pmcid: 5707411
doi: 10.1038/s41467-017-01858-w
Pandya MC, Callahan SM, Savchenko KG, Stobart CC. A contemporary view of respiratory syncytial virus (RSV) biology and strain-specific differences. Pathogens. 2019;8(2):67.
Tan L, Lemey P, Houspie L, et al. Genetic variability among complete human respiratory syncytial virus subgroup A genomes: bridging molecular evolutionary dynamics and epidemiology. PLoS ONE. 2012;7(12):e51439.
pubmed: 23236501
pmcid: 3517519
doi: 10.1371/journal.pone.0051439
Anderson LJ, Hierholzer JC, Tsou C, et al. Antigenic characterization of respiratory syncytial virus strains with monoclonal antibodies. J Infect Dis. 1985;151(4):626–33.
pubmed: 2579169
doi: 10.1093/infdis/151.4.626
Mufson MA, Orvell C, Rafnar B, Norrby E. Two distinct subtypes of human respiratory syncytial virus. J Gen Virol. 1985;66(Pt 10):2111–24.
pubmed: 2413163
doi: 10.1099/0022-1317-66-10-2111
Muñoz-Escalante JC, Comas-García A, Bernal-Silva S, Noyola DE. Respiratory syncytial virus B sequence analysis reveals a novel early genotype. Sci Rep. 2021;11(1):3452.
pubmed: 33568737
pmcid: 7876121
doi: 10.1038/s41598-021-83079-2
Muñoz-Escalante JC, Comas-García A, Bernal-Silva S, Robles-Espinoza CD, Gómez-Leal G, Noyola DE. Respiratory syncytial virus A genotype classification based on systematic intergenotypic and intragenotypic sequence analysis. Sci Rep. 2019;9(1):20097.
pubmed: 31882808
pmcid: 6934736
doi: 10.1038/s41598-019-56552-2
Tan L, Coenjaerts FE, Houspie L, et al. The comparative genomics of human respiratory syncytial virus subgroups A and B: genetic variability and molecular evolutionary dynamics. J Virol. 2013;87(14):8213–26.
pubmed: 23698290
pmcid: 3700225
doi: 10.1128/JVI.03278-12
Schobel SA, Stucker KM, Moore ML, et al. Respiratory syncytial virus whole-genome sequencing identifies convergent evolution of sequence duplication in the C-terminus of the G gene. Sci Rep. 2016;6:26311.
pubmed: 27212633
pmcid: 4876326
doi: 10.1038/srep26311
Shishir TA, Saha O, Rajia S, et al. Genome-wide study of globally distributed respiratory syncytial virus (RSV) strains implicates diversification utilizing phylodynamics and mutational analysis. Sci Rep. 2023;13(1):13531.
pubmed: 37598270
pmcid: 10439963
doi: 10.1038/s41598-023-40760-y
Eshaghi A, Duvvuri VR, Lai R, et al. Genetic variability of human respiratory syncytial virus A strains circulating in Ontario: a novel genotype with a 72 nucleotide G gene duplication. PLoS ONE. 2012;7(3):e32807.
pubmed: 22470426
pmcid: 3314658
doi: 10.1371/journal.pone.0032807
Trento A, Casas I, Calderón A, et al. Ten years of global evolution of the human respiratory syncytial virus BA genotype with a 60-nucleotide duplication in the G protein gene. J Virol. 2010;84(15):7500–12.
pubmed: 20504933
pmcid: 2897623
doi: 10.1128/JVI.00345-10
Liang X, Liu DH, Chen D, et al. Gradual replacement of all previously circulating respiratory syncytial virus A strain with the novel ON1 genotype in Lanzhou from 2010 to 2017. Medicine (Baltimore). 2019;98(19):e15542.
pubmed: 31083208
doi: 10.1097/MD.0000000000015542
Yassine HM, Sohail MU, Younes N, Nasrallah GK. Systematic review of the respiratory syncytial virus (RSV) prevalence, genotype distribution, and seasonality in children from the Middle East and North Africa (MENA) region. Microorganisms. 2020;8(5):713.
pubmed: 32403364
pmcid: 7284433
doi: 10.3390/microorganisms8050713
Lee CY, Wu TH, Fang YP, et al. Delayed respiratory syncytial virus outbreak in 2020 in Taiwan was correlated with two novel RSV-A genotype ON1 variants. Influenza Other Respir Viruses. 2022;16(3):511–20.
pubmed: 34913593
doi: 10.1111/irv.12951
Yun KW, Choi EH, Lee HJ. Molecular epidemiology of respiratory syncytial virus for 28 consecutive seasons (1990–2018) and genetic variability of the duplication region in the G gene of genotypes ON1 and BA in South Korea. Arch Virol. 2020;165(5):1069–77.
pubmed: 32144544
doi: 10.1007/s00705-020-04580-z
Robertson M, Eden JS, Levy A, et al. The spatial-temporal dynamics of respiratory syncytial virus infections across the east-west coasts of Australia during 2016–17. Virus Evol. 2021;7(2):veab068.
pubmed: 34532066
pmcid: 8438877
doi: 10.1093/ve/veab068
Tabatabai J, Ihling CM, Rehbein RM, et al. Molecular epidemiology of respiratory syncytial virus in hospitalised children in Heidelberg, Southern Germany, 2014–2017. Infect Genet Evol. 2022;98:105209.
pubmed: 35032683
doi: 10.1016/j.meegid.2022.105209
Luo Q, Li M, Li A, et al. Genetic diversity and epidemiological features of respiratory syncytial virus, Beijing, 2015–2019: a multicenter and all-age groups study. J Infect. 2022;85(1):75–85.
pubmed: 35533834
doi: 10.1016/j.jinf.2022.04.046
Gimferrer L, Vila J, Piñana M, et al. Virological surveillance of human respiratory syncytial virus A and B at a tertiary hospital in Catalonia (Spain) during five consecutive seasons (2013–2018). Future Microbiol. 2019;14:373–81.
pubmed: 30860397
doi: 10.2217/fmb-2018-0261
Lee YE, Choi OK, Bang SJ, et al. Molecular epidemiological study of the G protein of human respiratory syncytial virus detected in patients with acute respiratory infections in Gyeonggi Province, South Korea. J Med Virol. 2022;94(2):549–56.
pubmed: 34730256
doi: 10.1002/jmv.27431
Tabor DE, Fernandes F, Langedijk AC, et al. Global molecular epidemiology of respiratory syncytial virus from the 2017–2018 INFORM-RSV study. J Clin Microbiol. 2020;59(1):e01828-20.
Hotard AL, Laikhter E, Brooks K, Hartert TV, Moore ML. Functional analysis of the 60-nucleotide duplication in the respiratory syncytial virus buenos aires strain attachment glycoprotein. J Virol. 2015;89(16):8258–66.
pubmed: 26018171
pmcid: 4524256
doi: 10.1128/JVI.01045-15
Graham BS, Modjarrad K, McLellan JS. Novel antigens for RSV vaccines. Curr Opin Immunol. 2015;35:30–8.
pubmed: 26070108
pmcid: 4553118
doi: 10.1016/j.coi.2015.04.005
McLellan JS, Chen M, Leung S, et al. Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Science. 2013;340(6136):1113–7.
pubmed: 23618766
pmcid: 4459498
doi: 10.1126/science.1234914
Ruckwardt TJ, Morabito KM, Graham BS. Immunological lessons from respiratory syncytial virus vaccine development. Immunity. 2019;51(3):429–42.
pubmed: 31533056
doi: 10.1016/j.immuni.2019.08.007
Gilman MS, Castellanos CA, Chen M, et al. Rapid profiling of RSV antibody repertoires from the memory B cells of naturally infected adult donors. Sci Immunol. 2016;1(6):eaaj1879.
Mousa JJ, Kose N, Matta P, Gilchuk P, Crowe JE Jr. A novel pre-fusion conformation-specific neutralizing epitope on the respiratory syncytial virus fusion protein. Nat Microbiol. 2017;2:16271.
pubmed: 28134924
pmcid: 5463187
doi: 10.1038/nmicrobiol.2016.271
Ngwuta JO, Chen M, Modjarrad K, et al. Prefusion F-specific antibodies determine the magnitude of RSV neutralizing activity in human sera. Sci Transl Med. 2015;7(309):309ra162.
pubmed: 26468324
pmcid: 4672383
doi: 10.1126/scitranslmed.aac4241
Xiao X, Tang A, Cox KS, et al. Characterization of potent RSV neutralizing antibodies isolated from human memory B cells and identification of diverse RSV/hMPV cross-neutralizing epitopes. MAbs. 2019;11(8):1415–27.
pubmed: 31402751
pmcid: 6816417
doi: 10.1080/19420862.2019.1654304
Mas V, Nair H, Campbell H, Melero JA, Williams TC. Antigenic and sequence variability of the human respiratory syncytial virus F glycoprotein compared to related viruses in a comprehensive dataset. Vaccine. 2018;36(45):6660–73.
pubmed: 30292456
pmcid: 6203811
doi: 10.1016/j.vaccine.2018.09.056
Chen X, Xu B, Guo J, et al. Genetic variations in the fusion protein of respiratory syncytial virus isolated from children hospitalized with community-acquired pneumonia in China. Sci Rep. 2018;8(1):4491.
pubmed: 29540836
pmcid: 5852162
doi: 10.1038/s41598-018-22826-4
Lu B, Liu H, Tabor DE, et al. Emergence of new antigenic epitopes in the glycoproteins of human respiratory syncytial virus collected from a US surveillance study, 2015–17. Sci Rep. 2019;9(1):3898.
doi: 10.1038/s41598-019-40387-y
Zhou X, Jiang M, Wang F, et al. Immune escaping of the novel genotypes of human respiratory syncytial virus based on gene sequence variation. Front Immunol. 2022;13:1084139.
pubmed: 36703972
doi: 10.3389/fimmu.2022.1084139
Widjaja I, Wicht O, Luytjes W, et al. Characterization of epitope-specific anti-respiratory syncytial virus (anti-RSV) antibody responses after natural infection and after vaccination with formalin-inactivated RSV. J Virol. 2016;90(13):5965–77.
pubmed: 27099320
pmcid: 4907225
doi: 10.1128/JVI.00235-16
Tang A, Chen Z, Cox KS, et al. A potent broadly neutralizing human RSV antibody targets conserved site IV of the fusion glycoprotein. Nat Commun. 2019;10(1):4153.
pubmed: 31515478
pmcid: 6742648
doi: 10.1038/s41467-019-12137-1
Crank MC, Ruckwardt TJ, Chen M, et al. A proof of concept for structure-based vaccine design targeting RSV in humans. Science. 2019;365(6452):505–9.
pubmed: 31371616
doi: 10.1126/science.aav9033
Falsey AR, Walsh EE, Scott DA, et al. Phase 1/2 randomized study of the immunogenicity, safety, and tolerability of a respiratory syncytial virus prefusion F vaccine in adults with concomitant inactivated influenza vaccine. J Infect Dis. 2022;225(12):2056–66.
pubmed: 34931667
doi: 10.1093/infdis/jiab611
Pierangeli A, Viscido A, Bitossi C, et al. Differential interferon gene expression in bronchiolitis caused by respiratory syncytial virus-A genotype ON1. Med Microbiol Immunol. 2020;209(1):23–8.
pubmed: 31485724
doi: 10.1007/s00430-019-00633-6
Russell CD, Unger SA, Walton M, Schwarze J. The human immune response to respiratory syncytial virus infection. Clin Microbiol Rev. 2017;30(2):481–502.
pubmed: 28179378
pmcid: 5355638
doi: 10.1128/CMR.00090-16
Chen J, Tan S, Avadhanula V, et al. Diversity and evolution of computationally predicted T cell epitopes against human respiratory syncytial virus. PLoS Comput Biol. 2023;19(1):e1010360.
pubmed: 36626370
pmcid: 9870173
doi: 10.1371/journal.pcbi.1010360
Blunck BN, Angelo LS, Henke D, et al. Adult memory T cell responses to the respiratory syncytial virus fusion protein during a single RSV season (2018–2019). Front Immunol. 2022;13:823652.
pubmed: 35422803
pmcid: 9002099
doi: 10.3389/fimmu.2022.823652
Jones HG, Battles MB, Lin CC, Bianchi S, Corti D, McLellan JS. Alternative conformations of a major antigenic site on RSV F. PLoS Pathog. 2019;15(7):e1007944.
pubmed: 31306469
pmcid: 6658013
doi: 10.1371/journal.ppat.1007944
Zhu Q, McLellan JS, Kallewaard NL, et al. A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants. Sci Transl Med. 2017;9(388):eaaj1928.
Simões EAF, Madhi SA, Muller WJ, et al. Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials. Lancet Child Adolesc Health. 2023;7(3):180–9.
pubmed: 36634694
pmcid: 9940918
doi: 10.1016/S2352-4642(22)00321-2
Griffin MP, Yuan Y, Takas T, et al. Single-dose nirsevimab for prevention of RSV in preterm infants. N Engl J Med. 2020;383(5):415–25.
pubmed: 32726528
doi: 10.1056/NEJMoa1913556
Lin GL, Drysdale SB, Snape MD, et al. Distinct patterns of within-host virus populations between two subgroups of human respiratory syncytial virus. Nat Commun. 2021;12(1):5125.
pubmed: 34446722
pmcid: 8390747
doi: 10.1038/s41467-021-25265-4
Wilkins D, Langedijk AC, Lebbink RJ, et al. Nirsevimab binding-site conservation in respiratory syncytial virus fusion glycoprotein worldwide between 1956 and 2021: an analysis of observational study sequencing data. Lancet Infect Dis. 2023;23(7):856–66.
Simões EAF, Forleo-Neto E, Geba GP, et al. Suptavumab for the prevention of medically attended respiratory syncytial virus infection in preterm infants. Clin Infect Dis. 2021;73(11):e4400–8.
pubmed: 32897368
doi: 10.1093/cid/ciaa951
Phuah JY, Maas BM, Tang A, et al. Quantification of clesrovimab, an investigational, half-life extended, anti-respiratory syncytial virus protein F human monoclonal antibody in the nasal epithelial lining fluid of healthy adults. Biomed Pharmacother. 2023;169:115851.
pubmed: 37976891
doi: 10.1016/j.biopha.2023.115851
Mufson MA, Akerlind-Stopner B, Orvell C, Belshe RB, Norrby E. A single-season epidemic with respiratory syncytial virus subgroup B2 during 10 epidemic years, 1978 to 1988. J Clin Microbiol. 1991;29(1):162–5.
pubmed: 1993752
pmcid: 269722
doi: 10.1128/jcm.29.1.162-165.1991
Mufson MA, Belshe RB, Orvell C, Norrby E. Respiratory syncytial virus epidemics: variable dominance of subgroups A and B strains among children, 1981–1986. J Infect Dis. 1988;157(1):143–8.
pubmed: 3335796
doi: 10.1093/infdis/157.1.143
Heikkinen T, Waris M, Ruuskanen O, Putto-Laurila A, Mertsola J. Incidence of acute otitis media associated with group A and B respiratory syncytial virus infections. Acta Paediatr. 1995;84(4):419–23.
pubmed: 7795353
doi: 10.1111/j.1651-2227.1995.tb13663.x
Tsutsumi H, Onuma M, Nagai K, Yamazaki H, Chiba S. Clinical characteristics of respiratory syncytial virus (RSV) subgroup infections in Japan. Scand J Infect Dis. 1991;23(6):671–4.
pubmed: 1815326
doi: 10.3109/00365549109024291
Monto AS, Ohmit S. Respiratory syncytial virus in a community population: circulation of subgroups A and B since 1965. J Infect Dis. 1990;161(4):781–3.
pubmed: 2319169
doi: 10.1093/infdis/161.4.781
Hendry RM, Talis AL, Godfrey E, Anderson LJ, Fernie BF, McIntosh K. Concurrent circulation of antigenically distinct strains of respiratory syncytial virus during community outbreaks. J Infect Dis. 1986;153(2):291–7.
pubmed: 2418126
doi: 10.1093/infdis/153.2.291
Russi JC, Delfraro A, Arbiza JR, et al. Antigenic characterization of respiratory syncytial virus associated with acute respiratory infections in Uruguayan children from 1985 to 1987. J Clin Microbiol. 1989;27(7):1464–6.
pubmed: 2671013
pmcid: 267595
doi: 10.1128/jcm.27.7.1464-1466.1989
Wilson E, Orvell C, Morrison B, Thomas E. Pediatric RSV infection during two winter seasons in British Columbia: a role for subgroup analysis in young children? Can J Infect Dis. 1990;1(4):112–6.
pubmed: 22553451
pmcid: 3327979
McIntosh ED, De Silva LM, Oates RK. Clinical severity of respiratory syncytial virus group A and B infection in Sydney. Aust Pediatr Infect Dis J. 1993;12(10):815–9.
doi: 10.1097/00006454-199310000-00004
Fletcher JN, Smyth RL, Thomas HM, Ashby D, Hart CA. Respiratory syncytial virus genotypes and disease severity among children in hospital. Arch Dis Child. 1997;77(6):508–11.
pubmed: 9496185
pmcid: 1717415
doi: 10.1136/adc.77.6.508
Kneyber MC, Brandenburg AH, Rothbarth PH, de Groot R, Ott A, van Steensel-Moll HA. Relationship between clinical severity of respiratory syncytial virus infection and subtype. Arch Dis Child. 1996;75(2):137–40.
pubmed: 8869195
pmcid: 1511617
doi: 10.1136/adc.75.2.137
Wang EE, Law BJ, Stephens D. Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) prospective study of risk factors and outcomes in patients hospitalized with respiratory syncytial viral lower respiratory tract infection. J Pediatr. 1995;126(2):212–9.
pubmed: 7844667
doi: 10.1016/S0022-3476(95)70547-3
Agoti CN, Mwihuri AG, Sande CJ, et al. Genetic relatedness of infecting and reinfecting respiratory syncytial virus strains identified in a birth cohort from rural Kenya. J Infect Dis. 2012;206(10):1532–41.
pubmed: 22966119
pmcid: 3475639
doi: 10.1093/infdis/jis570
Kaplan NM, Dove W, Abd-Eldayem SA, Abu-Zeid AF, Shamoon HE, Hart CA. Molecular epidemiology and disease severity of respiratory syncytial virus in relation to other potential pathogens in children hospitalized with acute respiratory infection in Jordan. J Med Virol. 2008;80(1):168–74.
pubmed: 18041044
doi: 10.1002/jmv.21067
Paulus SC, Hirschfeld AF, Victor RE, Brunstein J, Thomas E, Turvey SE. Common human Toll-like receptor 4 polymorphisms-role in susceptibility to respiratory syncytial virus infection and functional immunological relevance. Clin Immunol. 2007;123(3):252–7.
pubmed: 17449325
doi: 10.1016/j.clim.2007.03.003
Rodriguez-Fernandez R, Tapia LI, Yang CF, et al. Respiratory syncytial virus genotypes, host immune profiles, and disease severity in young children hospitalized with bronchiolitis. J Infect Dis. 2017;217(1):24–34.
pubmed: 29045741
pmcid: 5853407
doi: 10.1093/infdis/jix543
Fodha I, Vabret A, Ghedira L, et al. Respiratory syncytial virus infections in hospitalized infants: association between viral load, virus subgroup, and disease severity. J Med Virol. 2007;79(12):1951–8.
pubmed: 17935185
doi: 10.1002/jmv.21026
Midulla F, Nenna R, Scagnolari C, et al. How respiratory syncytial virus genotypes influence the clinical course in infants hospitalized for bronchiolitis. J Infect Dis. 2019;219(4):526–34.
pubmed: 30204889
doi: 10.1093/infdis/jiy496
Yoshihara K, Le MN, Okamoto M, et al. Association of RSV-A ON1 genotype with increased pediatric acute lower respiratory tract infection in Vietnam. Sci Rep. 2016;6:27856.
pubmed: 27306333
pmcid: 4910061
doi: 10.1038/srep27856
Panayiotou C, Richter J, Koliou M, Kalogirou N, Georgiou E, Christodoulou C. Epidemiology of respiratory syncytial virus in children in Cyprus during three consecutive winter seasons (2010–2013): age distribution, seasonality and association between prevalent genotypes and disease severity. Epidemiol Infect. 2014;142(11):2406–11.
pubmed: 24476750
doi: 10.1017/S0950268814000028
Gamiño-Arroyo AE, Moreno-Espinosa S, Llamosas-Gallardo B, et al. Epidemiology and clinical characteristics of respiratory syncytial virus infections among children and adults in Mexico. Influenza Other Respir Viruses. 2017;11(1):48–56.
pubmed: 27439650
doi: 10.1111/irv.12414
Oladokun R, Muloiwa R, Hsiao NY, Valley-Omar Z, Nuttall J, Eley B. Clinical characterisation and phylogeny of respiratory syncytial virus infection in hospitalised children at Red Cross War Memorial Children’s Hospital, Cape Town. BMC Infect Dis. 2016;16:236.
pubmed: 27246848
pmcid: 4888648
doi: 10.1186/s12879-016-1572-5
Hibino A, Saito R, Taniguchi K, et al. Molecular epidemiology of human respiratory syncytial virus among children in Japan during three seasons and hospitalization risk of genotype ON1. PLoS ONE. 2018;13(1):e0192085.
pubmed: 29377949
pmcid: 5788364
doi: 10.1371/journal.pone.0192085
Valley-Omar Z, Tempia S, Hellferscee O, et al. Human respiratory syncytial virus diversity and epidemiology among patients hospitalized with severe respiratory illness in South Africa, 2012–2015. Influenza Other Respir Viruses. 2022;16(2):222–35.
pubmed: 34528769
doi: 10.1111/irv.12905
Yoon JG, Noh JY, Choi WS, et al. Clinical characteristics and disease burden of respiratory syncytial virus infection among hospitalized adults. Sci Rep. 2020;10(1):12106.
pubmed: 32694533
pmcid: 7374583
doi: 10.1038/s41598-020-69017-8
Espinosa Y, San Martín C, Torres AA, et al. Genomic loads and genotypes of respiratory syncytial virus: viral factors during lower respiratory tract infection in chilean hospitalized infants. Int J Mol Sci. 2017;18(3):654.
pubmed: 28335547
pmcid: 5372666
doi: 10.3390/ijms18030654
Utsunomiya T, Hibino A, Taniguchi K, et al. Factors contributing to symptom duration and viral reduction in outpatient children with respiratory syncytial virus infection. Pediatr Infect Dis J. 2020;39(8):678–83.
pubmed: 32101910
pmcid: 7360094
doi: 10.1097/INF.0000000000002626
Ciarlitto C, Vittucci AC, Antilici L, et al. Respiratory syncityal virus A and B: three bronchiolitis seasons in a third level hospital in Italy. Ital J Pediatr. 2019;45(1):115.
pubmed: 31462274
pmcid: 6712785
doi: 10.1186/s13052-019-0704-0
Devincenzo JP. Natural infection of infants with respiratory syncytial virus subgroups A and B: a study of frequency, disease severity, and viral load. Pediatr Res. 2004;56(6):914–7.
pubmed: 15470202
doi: 10.1203/01.PDR.0000145255.86117.6A
Moreira FB, Rosario CS, Santos JS, et al. Molecular characterization and clinical epidemiology of human respiratory syncytial virus (HRSV) A and B in hospitalized children, Southern Brazil. J Med Virol. 2017;89(8):1489–93.
pubmed: 28213974
doi: 10.1002/jmv.24795
Papadopoulos NG, Gourgiotis D, Javadyan A, et al. Does respiratory syncytial virus subtype influences the severity of acute bronchiolitis in hospitalized infants? Respir Med. 2004;98(9):879–82.
pubmed: 15338801
doi: 10.1016/j.rmed.2004.01.009
Laham FR, Mansbach JM, Piedra PA, et al. Clinical profiles of respiratory syncytial virus subtypes A AND B among children hospitalized with bronchiolitis. Pediatr Infect Dis J. 2017;36(8):808–10.
pubmed: 28383391
pmcid: 5556381
doi: 10.1097/INF.0000000000001596
Taylor CE, Morrow S, Scott M, Young B, Toms GL. Comparative virulence of respiratory syncytial virus subgroups A and B. Lancet. 1989;1(8641):777–8.
pubmed: 2564579
doi: 10.1016/S0140-6736(89)92592-0
Hall CB, Walsh EE, Schnabel KC, et al. Occurrence of groups A and B of respiratory syncytial virus over 15 years: associated epidemiologic and clinical characteristics in hospitalized and ambulatory children. J Infect Dis. 1990;162(6):1283–90.
pubmed: 2230258
doi: 10.1093/infdis/162.6.1283
McConnochie KM, Hall CB, Walsh EE, Roghmann KJ. Variation in severity of respiratory syncytial virus infections with subtype. J Pediatr. 1990;117(1 Pt 1):52–62.
pubmed: 2115082
doi: 10.1016/S0022-3476(05)82443-6
Salomón HE, Avila MM, Cerqueiro MC, Orvell C, Weissenbacher M. Clinical and epidemiologic aspects of respiratory syncytial virus antigenic variants in Argentinian children. J Infect Dis. 1991;163(5):1167.
pubmed: 2019767
doi: 10.1093/infdis/163.5.1167
Walsh EE, McConnochie KM, Long CE, Hall CB. Severity of respiratory syncytial virus infection is related to virus strain. J Infect Dis. 1997;175(4):814–20.
pubmed: 9086135
doi: 10.1086/513976
Imaz MS, Sequeira MD, Videla C, et al. Clinical and epidemiologic characteristics of respiratory syncytial virus subgroups A and B infections in Santa Fe, Argentina. J Med Virol. 2000;61(1):76–80.
pubmed: 10745236
doi: 10.1002/(SICI)1096-9071(200005)61:1<76::AID-JMV12>3.0.CO;2-P
Martinello RA, Chen MD, Weibel C, Kahn JS. Correlation between respiratory syncytial virus genotype and severity of illness. J Infect Dis. 2002;186(6):839–42.
pubmed: 12198620
doi: 10.1086/342414
Tabarani CM, Bonville CA, Suryadevara M, et al. Novel inflammatory markers, clinical risk factors and virus type associated with severe respiratory syncytial virus infection. Pediatr Infect Dis J. 2013;32(12):e437–42.
pubmed: 23804121
pmcid: 3883981
doi: 10.1097/INF.0b013e3182a14407
Gilca R, De Serres G, Tremblay M, et al. Distribution and clinical impact of human respiratory syncytial virus genotypes in hospitalized children over 2 winter seasons. J Infect Dis. 2006;193(1):54–8.
pubmed: 16323132
doi: 10.1086/498526
Tran DN, Pham TM, Ha MT, et al. Molecular epidemiology and disease severity of human respiratory syncytial virus in Vietnam. PLoS ONE. 2013;8(1):e45436.
pubmed: 23349659
pmcid: 3551923
doi: 10.1371/journal.pone.0045436
Straliotto SM, Roitman B, Lima JB, Fischer GB, Siqueira MM. Respiratory syncytial virus (RSV) bronchiolitis: comparative study of RSV groups A and B infected children. Rev Soc Bras Med Trop. 1994;27(1):1–4.
pubmed: 8008913
doi: 10.1590/S0037-86821994000100001
Hornsleth A, Klug B, Nir M, et al. Severity of respiratory syncytial virus disease related to type and genotype of virus and to cytokine values in nasopharyngeal secretions. Pediatr Infect Dis J. 1998;17(12):1114–21.
pubmed: 9877358
doi: 10.1097/00006454-199812000-00003
Liu W, Chen D, Tan W, et al. Epidemiology and clinical presentations of respiratory syncytial virus subgroups A and B detected with multiplex real-time PCR. PLoS ONE. 2016;11(10):e0165108.
pubmed: 27764220
pmcid: 5072546
doi: 10.1371/journal.pone.0165108
Chen X, Zhu Y, Wang W, et al. A multi-center study on molecular epidemiology of human respiratory syncytial virus from children with acute lower respiratory tract infections in the mainland of China between 2015 and 2019. Virol Sin. 2021;36(6):1475–83.
pubmed: 34398429
pmcid: 8365132
doi: 10.1007/s12250-021-00430-7
Adhikari B, Hassan F, Harrison CJ, et al. A multi-center study to determine genetic variations in the fusion gene of respiratory syncytial virus (RSV) from children <2 years of age in the U.S. J Clin Virol. 2022;154:105223.
Tramuto F, Maida CM, Di Naro D, et al. Respiratory syncytial virus: new challenges for molecular epidemiology surveillance and vaccination strategy in patients with ILI/SARI. Vaccines (Basel). 2021;9(11):1334.
pubmed: 34835265
doi: 10.3390/vaccines9111334
Cantú-Flores K, Rivera-Alfaro G, Muñoz-Escalante JC, Noyola DE. Global distribution of respiratory syncytial virus A and B infections: a systematic review. Pathog Glob Health. 2022;116(7):398–409.
pubmed: 35156555
pmcid: 9518599
doi: 10.1080/20477724.2022.2038053
Falsey AR, Singh HK, Walsh EE. Serum antibody decay in adults following natural respiratory syncytial virus infection. J Med Virol. 2006;78(11):1493–7.
pubmed: 16998887
doi: 10.1002/jmv.20724
European Medicines Agency. First vaccine to protect older adults from respiratory syncytial virus (RSV) infection [press release]. 2023. https://www.ema.europa.eu/en/news/first-vaccine-protect-older-adults-respiratory-syncytial-virus-rsv-infection
US FDA. FDA approves first respiratory syncytial virus (RSV) vaccine—arexvy approved for individuals 60 years of age and older [press release]. 2023. https://www.fda.gov/news-events/press-announcements/fda-approves-first-respiratory-syncytial-virus-rsv-vaccine
European Medicines Agency. First RSV vaccine to protect infants up to 6 months of age and older adults [press release]. 2023. https://www.ema.europa.eu/en/news/first-rsv-vaccine-protect-infants-6-months-age-and-older-adults
US FDA. FDA approves first vaccine for pregnant individuals to prevent RSV in infants [press release]. 2023. https://www.fda.gov/news-events/press-announcements/fda-approves-first-vaccine-pregnant-individuals-prevent-rsv-infants
Schwarz TF, Johnson C, Grigat C, et al. Three dose levels of a maternal respiratory syncytial virus vaccine candidate are well tolerated and immunogenic in a randomized trial in nonpregnant women. J Infect Dis. 2022;225(12):2067–76.
pubmed: 34146100
doi: 10.1093/infdis/jiab317
Walsh EE, Pérez Marc G, Zareba AM, et al. Efficacy and safety of a bivalent RSV prefusion F vaccine in older adults. N Engl J Med. 2023;388(16):1465–77.
pubmed: 37018468
doi: 10.1056/NEJMoa2213836
Mukhamedova M, Wrapp D, Shen CH, et al. Vaccination with prefusion-stabilized respiratory syncytial virus fusion protein induces genetically and antigenically diverse antibody responses. Immunity. 2021;54(4):769–80.e6.
pubmed: 33823129
pmcid: 8099422
doi: 10.1016/j.immuni.2021.03.004
Joyce MG, Bao A, Chen M, et al. Crystal structure and immunogenicity of the DS-Cav1-stabilized fusion glycoprotein from respiratory syncytial virus subtype B. Pathog Immun. 2019;4(2):294–323.
pubmed: 31893251
pmcid: 6922093
doi: 10.20411/pai.v4i2.338
Leroux-Roels I, Davis MG, Steenackers K, et al. Safety and immunogenicity of a respiratory syncytial virus prefusion F (RSVPreF3) candidate vaccine in older adults: phase 1/2 randomized clinical trial. J Infect Dis. 2023;227(6):761–72.
pubmed: 35904987
doi: 10.1093/infdis/jiac327
Papi A, Ison MG, Langley JM, et al. Respiratory syncytial virus prefusion F protein vaccine in older adults. N Engl J Med. 2023;388(7):595–608.
pubmed: 36791160
doi: 10.1056/NEJMoa2209604
Walsh EE, Falsey AR, Scott DA, et al. A randomized phase 1/2 study of a respiratory syncytial virus prefusion F vaccine. J Infect Dis. 2022;225(8):1357–66.
pubmed: 34932102
doi: 10.1093/infdis/jiab612
Ison MG, Papi A, Athan E, et al. Efficacy and safety of respiratory syncytial virus prefusion F protein vaccine (RSVPreF3 OA) in older adults over 2 RSV seasons. Clin Infect Dis. 2024;78(6):1732–44.
https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-positive-top-line-data-full-season-two [press release]. 2024. Accessed 29 Feb 2024.
Das R. Overview of Moderna’s investigational RSV vaccine (mRNA-1345) in adults ≥ 60 years of age. CDC Advisory Committee on Immunization Practices (ACIP). 19-Feb-2024. https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2024-02-28-29/02-RSV-Adults-Das-508.pdf .
Che Y, Gribenko AV, Song X, et al. Rational design of a highly immunogenic prefusion-stabilized F glycoprotein antigen for a respiratory syncytial virus vaccine. Sci Transl Med. 2023;15:6422.
doi: 10.1126/scitranslmed.ade6422